Edgewise Therapeutics, Inc. Proceeds from Issuance of Debt
Edgewise Therapeutics, Inc. (EWTX) reported Proceeds from Issuance of Debt of $35.00 thousand for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-03.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfDebt · last filed 2022-11-03
- 2022-09-30: Proceeds from Issuance of Debt 9 month $35.00K.
| Period end | Proceeds from Issuance of Debt 9 month |
|---|---|
| 2022-09-30 | $35.00K 10-Q · filed 2022-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |